Compare
Seer, Inc. vs Precipio, Inc. vs Bionano Genomics, Inc. vs EyePoint, Inc.
| Latest fiscal year | Seer, Inc. SEER | Precipio, Inc. PRPO | Bionano Genomics, Inc. BNGO | EyePoint, Inc. EYPT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $16.58M | $24.05M | $28.51M | $31.37M |
| Revenue growth (YoY) | +17.0% | +29.8% | -7.4% | -27.5% |
| Gross margin | 51.1% | 44.5% | 46.3% (computed) | n/a |
| Operating margin | -470.5% | -5.0% | -116.9% | -776.0% |
| Net margin | -444.0% | -1.5% | -92.6% | -739.4% |
| Net income | -$73.60M | -$363.0K | -$26.39M | -$231.96M |
| EPS (Diluted) | n/a | -$0.23 | -$4.85 | -$3.17 |
| Operating cash flow | -$44.45M | $685.0K | -$16.34M | -$240.11M |
| Free cash flow | -$46.24M | $359.0K | n/a | -$243.39M |
| Cash & equivalents | $47.28M | $2.65M | $2.99M | $101.82M |
| Total assets | $296.08M | $21.32M | $73.58M | $364.00M |
| Total liabilities | $36.78M | $6.76M | $29.16M | $57.88M |
| Shareholders' equity | $259.31M | $14.56M | $44.42M | $306.11M |
| Return on year-end equity | -28.4% | -2.5% | -59.4% | -75.8% |
| Shares outstanding | n/a | 1.78M | 10.74M | 82.83M |
Revenue, most recent five fiscal years
| Fiscal year | Seer, Inc. | Precipio, Inc. | Bionano Genomics, Inc. | EyePoint, Inc. |
|---|---|---|---|---|
| Latest | $16.58M Ended 2025-12-31 | $24.05M Ended 2025-12-31 | $28.51M Ended 2025-12-31 | $31.37M Ended 2025-12-31 |
| 1 year earlier | $14.17M Ended 2024-12-31 | $18.53M Ended 2024-12-31 | $30.78M Ended 2024-12-31 | $43.27M Ended 2024-12-31 |
| 2 years earlier | $16.66M Ended 2023-12-31 | $15.20M Ended 2023-12-31 | $36.12M Ended 2023-12-31 | $46.02M Ended 2023-12-31 |
| 3 years earlier | $15.49M Ended 2022-12-31 | $9.41M Ended 2022-12-31 | $27.80M Ended 2022-12-31 | $41.40M Ended 2022-12-31 |
| 4 years earlier | $6.62M Ended 2021-12-31 | $8.85M Ended 2021-12-31 | $17.98M Ended 2021-12-31 | $36.94M Ended 2021-12-31 |